1. Home
  2. QTTB vs NAII Comparison

QTTB vs NAII Comparison

Compare QTTB & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • NAII
  • Stock Information
  • Founded
  • QTTB 2015
  • NAII 1980
  • Country
  • QTTB United States
  • NAII United States
  • Employees
  • QTTB N/A
  • NAII N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • NAII Medicinal Chemicals and Botanical Products
  • Sector
  • QTTB Health Care
  • NAII Health Care
  • Exchange
  • QTTB Nasdaq
  • NAII Nasdaq
  • Market Cap
  • QTTB 23.3M
  • NAII 21.2M
  • IPO Year
  • QTTB N/A
  • NAII 1987
  • Fundamental
  • Price
  • QTTB $1.67
  • NAII $3.71
  • Analyst Decision
  • QTTB Hold
  • NAII
  • Analyst Count
  • QTTB 8
  • NAII 0
  • Target Price
  • QTTB $24.00
  • NAII N/A
  • AVG Volume (30 Days)
  • QTTB 104.5K
  • NAII 4.5K
  • Earning Date
  • QTTB 08-06-2025
  • NAII 09-26-2025
  • Dividend Yield
  • QTTB N/A
  • NAII N/A
  • EPS Growth
  • QTTB N/A
  • NAII N/A
  • EPS
  • QTTB N/A
  • NAII N/A
  • Revenue
  • QTTB N/A
  • NAII $125,483,000.00
  • Revenue This Year
  • QTTB N/A
  • NAII N/A
  • Revenue Next Year
  • QTTB N/A
  • NAII N/A
  • P/E Ratio
  • QTTB N/A
  • NAII N/A
  • Revenue Growth
  • QTTB N/A
  • NAII 4.39
  • 52 Week Low
  • QTTB $1.35
  • NAII $2.57
  • 52 Week High
  • QTTB $53.79
  • NAII $6.88
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 42.51
  • NAII 49.64
  • Support Level
  • QTTB $1.62
  • NAII $3.58
  • Resistance Level
  • QTTB $1.82
  • NAII $4.03
  • Average True Range (ATR)
  • QTTB 0.16
  • NAII 0.11
  • MACD
  • QTTB -0.02
  • NAII -0.03
  • Stochastic Oscillator
  • QTTB 10.42
  • NAII 28.89

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

Share on Social Networks: